Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Possible Link Between Montelukast and Suicidality, US FDA Investigates WASHINGTON, DC -- March 27, 2008 -- The US Food and Drug Administration has informed healthcare professionals and patients of the agency's investigation of a possible association between the use of montelukast (Singulair) and behaviour/mood changes, suicidality, and suicide. Montelukast is a leukotriene receptor antagonist used to treat asthma and the symptoms of allergic rhinitis and to prevent exercise-induced asthma. The FDA issued an "Early Communication" stating that the agency is working with Merck & Co, Inc., makers of Singulair, to further evaluate a possible link between use of the drug and behaviour/mood changes, suicidality, and suicide in response to inquiries received by the FDA. The agency has requested that Merck evaluate montelukast study data for more information about suicidality and suicide. The FDA is reviewing the postmarketing reports it has received regarding behaviour/mood changes, suicidality, and suicide in patients who took montelukast. Due to the complexity of the analyses, the FDA anticipates that it may take up to 9 months to complete the ongoing evaluations. As soon as this review is complete, the FDA will communicate the conclusions and recommendations to the public. Until further information is available, healthcare professionals and caregivers should monitor patients taking montelukast for suicidality and changes in behaviour and mood. Other leukotriene modifying medications include zafirlukast (Accolate), which is also a leukotriene receptor antagonist, and zileuton (Zyflo and Zyflo CR), which is a leukotriene synthesis inhibitor. The FDA is reviewing postmarketing reports it has received of behaviour/mood changes, suicidality, and suicide in patients who took these drugs and will assess whether further investigation is warranted. The FDA urges both healthcare professionals and patients to report side effects from the use of montelukast, zafirlukast, and zileuton to the FDA's MedWatch Adverse Event Reporting program. Source: US Food and Drug Administration E-mail this page to a friend or colleague! To print, use this version